Annexin A1 (ANXA1) is a calcium-dependent phospholipid-linked protein that is associated with anti-inflammatory effects, regulation of cellular differentiation, proliferation, and apoptosis. In gastric cancer, ANXA1 is upregulated and has a significant role of gastric tumorigenesis. Although ANXA1 is known to be a p53 target gene, the association between ANXA1 expression and p53 expression is yet to be fully investigated in gastric cancer. We therefore investigated in this study the expressions of ANXA1 and p53 by immunohistochemical (IHC) staining in 231 gastric cancer tumors. ANXA1 expression was positive in 108 cases (46.8%), whereas negative in 123 cases (53.2%). p53 expression was positive in 109 cases (47.2%), but negative in 122 cases (52.8%). The percentage of positive ANXA1 was significantly higher in p53 positive tumors compared with p53 negative tumors (P < 0.001). We next performed IHC staining for ANXA1 and p53 in three human gastric cancer cell lines (MKN28, NUGU4, KATOIII). Positive staining for ANXA1 and p53 was detected in MKN28 cells with TP53 gene mutations. On the other hand, weak positive staining for ANXA1 and positive staining for p53 was found in NUGC4 and KATOIII cells with TP53 wild-type and truncating mutations, respectively. Our results demonstrated that ANXA1 is upregulated in p53-positive gastric cancer. ANXA1 expression may be induced by aberrant p53 protein, providing the possibility that ANXA1 works with the TP53 gene in gastric cancer.
Introduction
Annexin A1 (ANXA1) is a key member of the annexin superfamily and is a 37 kDa calcium-dependent phospholipid-linked protein involved in apoptosis, antiinflammatory effects, and the regulation of cellular differentiation and proliferation 1, 2) . Therefore, the ectopic expression of ANXA1 is thought to drive various cancer developments 2, 3) . We previously reported that a breast cancer case of positive ANXA1 expression by immunohistochemical (IHC) staining was frequently identified in triple-negative breast cancer (P = 0.007) and was associated with positive venous invasion (P = 0.028) 4) . We also reported that ANXA1 enhanced breast cancer invasion and metastasis under hypoxia in in vitro cell experiments, indicating that ANXA1 was apparently associated with breast cancer progression 4) . In addition, we stated that colon cancer cases with positive ANXA1 expression by IHC staining were associated with lymphatic invasion (P = 0.011), venous invasion (P = 0.023), and lymph node metastasis (P = 0.042) 5) . The colon cancer cases with positive ANXA1 staining were not statistically associated with poor survival 5) . However, our recent findings suggested that upregulated ANXA1 expression may play a critical role in 5-FU resistance in colon cancer cells, indicating the association between ANXA1 and worsened colon cancer outcome 6) . In gastric cancer, ANXA1 is also thought to play a critical role in cancer development 7, 8) . We reported gastric cancer cases with positive ANXA1 expression by IHC staining that were associated with lymphatic invasion (P = 0.023), venous invasion (P = 0.002), and lymph node metastasis (P = 0.001) 5) . In addition, the gastric cancer cases with positive ANXA1 staining were significantly associated with poor survival (P = 0.005) 5) . According to a recent in vitro study, ANXA1 overexpression increased the expression of cleaved caspase-3 via p53 9) . ANXA1 is known to be a p53 target gene and interacts with p53 in the nucleus, promoting p53-mediated transcriptional activation and inducing apoptosis via the caspase-3 pathway 9) . These data suggest the importance of functional relationship between ANXA1 and p53 in cancer development. However, the expression status between ANXA1 and p53 in gastric cancer has yet to be determined.
In this study, we evaluated the expression of ANXA1 and p53 by IHC staining in gastric cancer tumors and cell lines. We then aimed at implicating the relationship between ANXA1 and p53 (TP53 gene mutation).
Materials and methods

Clinical patient samples.
A total of 231 gastric cancer patients, who had undergone surgical resection at Fukushima Medical University Hospital (Fukushima, Japan) between 2000 and 2014, were enrolled in the present study. Gastric cancer specimens from all patients were assessed by IHC staining. All patients were Japanese and no patient received chemotherapy or radiotherapy before surgery. Information regarding age, sex, tumor-node-metastasis (TNM) stage 10) , and pathological diagnosis, including lymphatic and/or venous invasion, differentiation, was retrospectively collected. The present study was approved by the Ethics Committee of Fukushima Medical University (Fukushima, Japan). Written informed consent was obtained from all patients.
Cell line culture
The gastric cancer cell lines used in this study were originally obtained from the American Type Culture Collection (Rockville, MD, USA) and were cultured in the recommended media with 10% fetal bovine serum (FBS). These monolayer cells were maintained in a 37°C incubator with 5% CO 2 . Cells were checked regularly under a light microscope and subcultured when they reached 80% to 90% confluence.
IHC staining and evaluation
IHC staining was performed as previously described 6, 11) . Briefly, gastric cancer cells were fixed in 10% formalin and embedded in paraffin, then cut into 4 μm sections and stained. Histological sections (thickness, 4 μm) were also fixed in 10% buffered formalin, using a polymer peroxidase method (EnVision+/HRP; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA). Following deparaffinization with xylene and rehydration using a descending alcohol series, the tissue sections were treated with 0.3% hydrogen peroxide in methanol for 30 min at room temperature to block endogenous peroxidase activity. Following rinsing in PBS, the sections were incubated with anti-ANXA1 (1:1,000; clone 29, BD Biosciences, San Jose, CA, USA) and anti-p53 (1:100; DO-7, Dako) at 4˚C overnight. The sections were washed again in PBS and treated with ready-to-use peroxidase-labeled polymer conjugated to goat anti-rabbit immunoglobulins (cat. no. SM801; EnVision + kit; Dako; Agilent Technologies, Inc.) as the secondary antibody for 30 min at room temperature. The staining was visualized with diaminobenzidine, followed by counterstaining with hematoxylin. Expression of ANXA1 and p53 proteins was investigated using optical microscopy (BX43; Olympus Corporation, Tokyo, Japan). The staining of each specimen was assessed at ×40 or ×400 magnification by two investigators, M.S. and K.S. (Fukushima Medical University School of Medicine, Fukushima, Japan), who were blinded to the patients' names and clinical outcomes. The percentage of positively stained cancer cells was determined in three randomly selected areas (size, 200×200 μm) from the tumor specimens. Percentage of positive cells examined was scored and examined as negative (0), weak positive (< 10%), positive (≥ 10%).
Statistical data analysis
Statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA). The Fisher's exact test was performed to analyze the contingency tables. P-values of < 0.05 were considered significant.
Results
ANXA1 and p53 expression in patients with gastric cancer
We performed IHC staining for ANXA1 and p53 in patients with gastric cancer (Fig. 1) . A total number of 231 gastric cancer tumor samples was included in this study (Table 1) . ANXA1 expression was positive in 108 cases (46.8%), but negative in 123 cases (53.2%). The expression of p53 was positive in 109 cases (47.2%); however, it was negative in 122 cases (52.8%). The percentage of positive ANXA1 was significantly higher in p53 positive tumors compared with that in p53 negative tumors (P < 0.001) ( Table 2 ).
ANXA1 and p53 expression in gastric cancer cell lines
We next performed IHC staining for ANXA1 and p53 in three human gastric cancer cell lines (MKN28, NUGU4, KATOIII). Positive staining for ANXA1 was detected in the nucleus and cytoplasm of MKN28 cells, while weak positive staining for ANXA1 was found in NUGC4 and KATOIII cells (Fig. 2) . On the other hand, positive staining for p53 was detected in the nucleus of MKN28 cells, while negative staining for p53 was detected in the nucleus of NUGC4 and KATOIII cells. The MKN28 well-differentiated adenocarcinoma cell line had missense mutation in the TP53 gene, expressing a mutant p53 (Table 3 ). The KATOIII signet ring cell carcinoma cell line had total deletion of the TP53 gene, resulting in negative staining for p53. The detection of upregulated ANXA1 in the MKN28 cell line suggested an association between ANXA1 and p53 expression, which induces TP53 gene mutation. 
Discussion
In this study, we demonstrated that ANXA1 is upregulated in p53 positive gastric cancer. The upregulated ANXA1 may promote tumorigenesis in gastric cancer, especially in the p53 positive tumor 5) . We previously reported that upregulated ANXA1 was associated with positive lymphatic and venous invasion and with positive lymph node metastasis in gastric cancer 5) . According to other reports, ANXA1 is a p53 target gene 9, 12) . These results suggest that ANXA1 is upregulated by p53-mediated transcriptional activation, resulting in promotion of gastric tumorigenesis.
It is well known that p53, a tumor suppressor protein, maintains genome stability and inhibits cell proliferation in response to DNA damage 13) . To prevent tumor growth and metastasis, p53 is activated by cell cycle checkpoints due to DNA damage to induce either apoptosis or senescence 14) . The TP53 gene encodes the p53 protein, and is the most frequently mutated gene in various cancers, including gastric cancer [15] [16] [17] [18] [19] . Based on The Cancer Genome Atlas (TCGA) analysis, gastric cancer is divided into four subtypes: tumors positive for Epstein-Barr virus (EBV), microsatellite unstable tumors, genomically stable (GS) tumors, and tumors with chromosomal instability (CIN) 19) . TP53 mutations were significantly more frequent in CIN tumors than in GS tumors. Furthermore, TP53 mutations were very rare in EBV-positive tumors. Multistep carcinogenesis theory of gastric cancer in- 
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KATOIII cludes gene aberrations of TP53, CDX2, ARID1A, and KRAS genes. Among them, TP53 is most frequently identified mutated gene in gastric cancer 19) . A previous study reported that TP53 gene mutations occur in late tumorigenesis contributing to the final transition to gastric cancer 20) . Another report, however, demonstrated that TP53 gene mutation and p53 accumulation occur in early tumorigenesis in intestinal type gastric carcinogenesis 21) . Additionally, another report stated that gastric cancer patients with Helicobacter pylori (H. pylori) infection had accumulated gene mutations including TP53 gene 22) . Because H. pylori infection is an early event in gastric tumorigenesis, TP53 mutations may occur in early tumorigenesis. The role of TP53 gene mutations in the gastric carcinogenesis has yet to be clarified.
In the current study, we evaluated p53 expression by IHC staining in gastric cancer tumors. In general, p53 protein is not detectable by IHC staining, because p53 is expressed at low levels and exists for a very short time in normal conditions. Therefore, it was considered that nuclear positivity for p53 staining denotes TP53 mutations in gastric cancer 23) . Our results suggested that ANXA1 is upregulated in gastric tumors with TP53 mutations. However, ANXA1 seemed to have not been upregulated in the tumor with truncating TP53 mutations showing negative staining for p53 24) . TP53 mutations are categorized on the basis of the p53 function into loss of tumorsuppressor properties (loss of function [LOF]) or gain of novel oncogenic properties (gain of function [GOF]) 13) . Therefore, different TP53 mutations have different biological functions and staining for p53. Our results suggested that GOF mutations in the TP53 gene induce ANXA1 expression in gastric tumor.
In conclusion, we reported that ANXA1 is upregulated in p53-positive gastric cancer. This suggests that modulating ANXA1 expression may be caused by aberrant p53 expression and provides evidence that ANXA1 works with TP53 gene in gastric cancer.
